Specialty Pharmacy

Modifying small white blood cells shows promise in treating immune disorders.

Marc O'Connor, Chief Operating Officer of Curant Health, discusses how to evaluate the short term cost of treatment with new hepatitis C drugs versus the long term cost of care.

Young adults reported having trouble navigating HealthCare.gov for a health insurance plan during the first Affordable Care Act (ACA) open enrollment period.

Necitumumab added to chemotherapy increases survival to nearly a year.

Physical aspects and quality of life issues improve with treatment.

The total cost of health must be considered in light of a potential cure.

Many patients experience distress from concerns over treatment and disease progression.

Heather Bonome, PharmD, director of Pharmacy Segment at URAC, discusses how accreditation programs can enhance health care overall.

The FDA is currently reviewing Teva's reslizumab treatment for adult and adolescent asthmatics with symptoms inadequately controlled by inhaled corticosteroid (ICS) regimens.

Either patient group in need of more intensive treatment to reduce surgery risk.

Duration of sleep and snoring may play a role in survival outcomes.

Top stories of the week on Specialty Pharmacy Times from June 8-12.

Agency notes that expedited approvals do not compromise quality standards.

Study finds greater unmet needs for basic services compared with male patients.

Early palliative care reduces costs more than traditional treatment standards.

Increasing number of urology practices working with specialty pharmacies.

The FDA has granted Breakthrough Therapy Designation to Roche's tocilizumab (Actemra/RoActemra) for the treatment of systemic sclerosis.

The federal Drug Quality and Security Act was signed into law in 2013 with the intent to hold pharmacy stakeholders accountable for identifying suspect drug products and reporting related issues.

Men with AR-V7 variant more likely to be resistant to hormone drugs.

Researchers find cooperation among viral variants that help hepatitis C to survive.

David D'Altorio, PharmD, senior vice president of health services at MedImpact Healthcare Systems, Inc, discusses methods to address the growing cost of specialty medications.

Drug is being evaluated for the treatment of patients who received at least 3 prior lines of therapy.

The FDA has approved Novartis's eltrombopag (Promacta) to treat a rare, chronic blood disorder in children.

In addition to treating hepatitis B virus infection, Novartis's antiviral drug telbivudine effectively protects against mother-to-infant transmission.

Glioblastoma treatment with surgical resection may benefit patients with worst prognoses.

Undertreated side effects in treatment of some colon and stomach cancers need to be addressed.

Comprehensive screening guidelines needed for populations with multiple risk factors.

Provider status legislation may be the signature pharmacy policy issue of 2015.